Tesaro Inc., of Waltham, Mass., reported net product revenue of $63.6 million for the third quarter, compared to a total of $41.8 million for the third quarter of 2017. Net revenue from PARP inhibitor Zejula (niraparib) increased 61 percent to $63.2 million, compared to $39.4 million for the third quarter of 2017.